Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Current Value
$281.101 Year Return
Current Value
$281.101 Year Return
Market Cap
$150.48B
P/E Ratio
35.85
1Y Stock Return
6.52%
1Y Revenue Growth
21.38%
Dividend Yield
2.96%
Price to Book
20.0
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CLFD | 42.59% | $398.66M | +4.48% | 0.00% |
LOCO | 41.97% | $361.37M | +39.70% | 0.00% |
BIIB | 40.94% | $22.65B | -32.30% | 0.00% |
GMAB | 40.57% | $13.02B | -33.87% | 0.00% |
QGEN | 40.26% | $9.05B | -1.92% | 0.00% |
BCO | 39.80% | $4.00B | +19.00% | 1.04% |
SEM | 39.74% | $4.79B | +59.80% | 1.35% |
SHO | 39.30% | $2.02B | +3.53% | 3.20% |
TSN | 38.86% | $21.95B | +31.14% | 3.11% |
RITM | 38.70% | $5.54B | +5.44% | 9.38% |
JYNT | 38.06% | $164.07M | +24.57% | 0.00% |
KBH | 37.65% | $5.71B | +46.75% | 1.21% |
PLYM | 37.38% | $842.88M | -11.32% | 5.12% |
FUN | 37.30% | $4.60B | -16.51% | 0.00% |
LXP | 37.27% | $2.70B | +9.82% | 5.66% |
STAG | 36.99% | $6.62B | +1.94% | 4.09% |
TRNO | 36.78% | $6.04B | +9.22% | 3.06% |
VRRM | 36.68% | $3.79B | +17.16% | 0.00% |
MSI | 36.67% | $81.46B | +52.34% | 0.80% |
SW | 36.53% | $13.78B | +15.02% | 1.14% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
INSG | 0.04% | $157.28M | +540.25% | 0.00% |
KSPI | -0.15% | $20.86B | +18.06% | 3.37% |
BACK | 0.16% | $1.76M | -32.90% | 0.00% |
UUU | -0.24% | $4.97M | -41.89% | 0.00% |
DQ | -0.32% | $1.20B | -29.81% | 0.00% |
SCKT | -0.38% | $10.88M | +15.32% | 0.00% |
PHAT | -0.50% | $640.70M | +29.96% | 0.00% |
AHCO | -0.50% | $1.31B | +17.07% | 0.00% |
FMS | -0.61% | $12.97B | +12.47% | 2.97% |
LPLA | 0.61% | $23.55B | +38.13% | 0.38% |
RELY | 0.64% | $3.96B | -7.42% | 0.00% |
STG | 0.69% | $35.67M | +7.92% | 0.00% |
EDR | 0.77% | $9.01B | +19.26% | 0.82% |
HIMS | 0.88% | $5.14B | +210.42% | 0.00% |
MSDL | -0.89% | $1.83B | +0.66% | 7.26% |
NTZ | 0.89% | $47.64M | -30.94% | 0.00% |
VKTX | 1.08% | $5.74B | +353.83% | 0.00% |
DDOG | 1.12% | $45.32B | +19.19% | 0.00% |
BEEM | -1.13% | $58.36M | -29.34% | 0.00% |
ARQ | 1.17% | $332.89M | +216.80% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SPT | -23.93% | $1.67B | -46.02% | 0.00% |
BTCT | -23.14% | $42.61M | +353.33% | 0.00% |
FTNT | -19.99% | $69.59B | +72.67% | 0.00% |
MNOV | -16.83% | $93.19M | +2.15% | 0.00% |
PRPO | -13.49% | $9.10M | -13.65% | 0.00% |
MAGN | -12.10% | $638.97M | -3.42% | 0.00% |
SHOP | -11.83% | $135.10B | +49.99% | 0.00% |
TCTM | -11.49% | $8.10M | -42.99% | 0.00% |
WPRT | -10.06% | $76.83M | -36.88% | 0.00% |
HUSA | -9.88% | $16.69M | -11.56% | 0.00% |
NET | -9.82% | $33.09B | +30.49% | 0.00% |
SMWB | -9.70% | $1.01B | +134.25% | 0.00% |
OTEX | -8.73% | $7.59B | -26.30% | 3.55% |
LUMO | -8.21% | $37.45M | +41.97% | 0.00% |
DT | -8.19% | $15.40B | -1.30% | 0.00% |
BOOM | -7.99% | $151.20M | -52.25% | 0.00% |
ALAR | -7.51% | $89.09M | +158.08% | 0.00% |
DMLP | -7.40% | $1.58B | +18.00% | 10.54% |
OMI | -5.84% | $956.92M | -33.32% | 0.00% |
GAN | -5.66% | $83.39M | +21.19% | 0.00% |
Yahoo
Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come.
Finnhub
On November 13, 2024, Amgen filed Case No. 5:24-cv-00642 against Accord BioPharma and Intas Pharmaceuticals, alleging INTP23, their proposed Prolia® / Xgeva® biosimilar, would infringe 34 of...
Yahoo
Amgen (NASDAQ:AMGN) today announced that Howard Chang, M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024. Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner, M.D., executive vice president of Research and Development.
Finnhub
By Stephen Nakrosis Amgen on Wednesday said Howard Chang will join the company as senior vice president of research, effective Dec. 16. The company said Chang, who will also serve as chief...
MarketWatch
Amgen Inc. stock outperforms competitors on strong trading day
Yahoo
Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBTE | -0.55% | $1.70B | 0.07% |
BCD | -0.58% | $245.02M | 0.3% |
CMDY | -0.69% | $279.14M | 0.28% |
KRBN | -0.80% | $242.47M | 0.85% |
KCCA | -0.97% | $220.51M | 0.87% |
DBMF | -1.08% | $1.02B | 0.85% |
CLOI | 1.27% | $715.40M | 0.4% |
TBIL | 1.63% | $4.38B | 0.15% |
BCI | -1.63% | $1.20B | 0.26% |
GBIL | 1.68% | $5.60B | 0.12% |
GCC | 1.79% | $133.23M | 0.55% |
HDRO | -1.95% | $164.26M | 0.3% |
HIGH | 2.01% | $302.78M | 0.51% |
DBA | -2.04% | $755.88M | 0.93% |
BOXX | 2.44% | $4.43B | 0.1949% |
AGZD | -2.87% | $142.76M | 0.23% |
TPMN | 2.98% | $40.60M | 0.65% |
SOYB | -3.00% | $27.32M | 0.22% |
FLTR | 3.07% | $1.79B | 0.14% |
USCI | -3.37% | $185.47M | 1.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -21.26% | $195.31M | 0.85% |
USDU | -20.51% | $201.97M | 0.5% |
UUP | -17.40% | $309.25M | 0.77% |
EQLS | -16.19% | $76.08M | 1% |
BTAL | -15.23% | $388.04M | 1.43% |
CTA | -13.91% | $350.27M | 0.78% |
KMLM | -11.91% | $353.87M | 0.9% |
DBO | -11.44% | $217.57M | 0.77% |
TAIL | -9.54% | $67.98M | 0.59% |
DBE | -9.49% | $50.13M | 0.77% |
GSG | -8.97% | $914.42M | 0.75% |
COMT | -8.90% | $829.06M | 0.48% |
PDBC | -8.28% | $4.40B | 0.59% |
DBC | -7.50% | $1.39B | 0.87% |
CANE | -6.54% | $17.72M | 0.29% |
CORN | -5.33% | $61.12M | 0.2% |
FMF | -4.39% | $244.61M | 0.95% |
FTGC | -3.51% | $2.17B | 1.02% |
WEAT | -3.51% | $120.27M | 0.28% |
USCI | -3.37% | $185.47M | 1.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BBH | 67.25% | $397.87M | 0.35% |
IBB | 61.04% | $6.66B | 0.45% |
VHT | 55.75% | $17.06B | 0.1% |
FHLC | 55.73% | $2.73B | 0.084% |
IYH | 54.86% | $3.19B | 0.39% |
XLV | 54.84% | $38.41B | 0.09% |
IXJ | 53.88% | $3.89B | 0.41% |
FBT | 53.58% | $1.11B | 0.56% |
PBE | 52.68% | $258.53M | 0.58% |
SCHD | 51.93% | $65.70B | 0.06% |
FXH | 51.66% | $1.15B | 0.62% |
RSPH | 50.57% | $885.96M | 0.4% |
DGRO | 48.66% | $30.46B | 0.08% |
USMV | 48.13% | $23.89B | 0.15% |
RSPA | 48.06% | $273.87M | 0% |
SPYV | 47.15% | $24.94B | 0.04% |
DIVO | 47.10% | $3.74B | 0.56% |
DIA | 47.02% | $38.06B | 0.16% |
VTV | 46.71% | $131.67B | 0.04% |
VOOV | 46.70% | $5.36B | 0.1% |